US Patent 9957526 Delivery methods and compositions for nuclease-mediated genome engineering
Patent 9957526 was granted and assigned to Sangamo Therapeutics on May, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 2 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Jan, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+136 characters)
Article
Patent abstract
The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell.
Edits on 1 Oct, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Jianbin Wang0
Michael C. Holmes0
Edits on 31 May, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09957526 Delivery methods and compositions for nuclease-mediated genome engineering US Patent 9957526 Delivery methods and compositions for nuclease-mediated genome engineering
Infobox
Patent Number
099575260
Patent Number
99575260
Edits on 26 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
Patent Jurisdiction
Patent Number
099575260
Date of Patent
May 1, 2018
0Patent Application Number
145162360
Date Filed
October 16, 2014
0Patent Primary Examiner
Edits on 20 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09957526 Delivery methods and compositions for nuclease-mediated genome engineering
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09957526
Date of patent
May 1, 2018
Patent application number
14516236
Date Filed
October 16, 2014
Patent primary examiner
Find more entities like US Patent 9957526 Delivery methods and compositions for nuclease-mediated genome engineering
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
